Skip to search formSkip to main contentSkip to account menu

Vandetanib

An orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor… 
National Institutes of Health

Related topics

Related topics

7 relations

Narrower (2)

CaprelsaZD 6474
NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase InhibitionVandetanib 300 MG Oral Tablet [Caprelsa]docetaxel/ZD6474

Broader (1)

Zactima

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Systemic treatment and management approaches for medullary thyroid cancer.
2015
2015
Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: A pooled analysis
The dermatologic adverse events (AEs) of various molecularly targeted therapies are well‐described in adult cancer patients… 
Review
2013
Review
2013
Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC).
Review
2013
Review
2013
Consensus recommendations on pathologic changes in the hippocampus: a postmortem multicenter inter-rater study.
There is no consensus on the pathologic conditions or severity implied by the term "hippocampal sclerosis" (HS). In this study, a… 
Review
2012
Review
2012
Targeted therapies for advanced non-small-cell lung cancer: current status and future implications.
2012
2012
Novel withanolides target medullary thyroid cancer through inhibition of both RET phosphorylation and the mammalian target of rapamycin pathway.
Review
2010
Review
2010
Molecularly targeted therapy in hepatocellular carcinoma.
Highly Cited
2009
Highly Cited
2009
Targeting RET for thyroid cancer therapy.
2009
2009
The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma.
This study was designed to determine the effects of vandetanib, a small-molecule receptor tyrosine kinase inhibitor of vascular… 
Review
2006
Review
2006
Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy.
In clinical trials thus far, single-targeted kinase inhibitors have shown only limited success in demonstrating survival benefits… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)